Clinical trial
Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration…
NCT02621931 · Teva Branded Pharmaceutical Products R&D, Inc., Industry · Completed
Key facts
| NCT number | NCT02621931 |
|---|---|
| Title | Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine |
| Official title | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of Fremanezumab (TEV-48125) Versus Placebo for the Preventive Treatment of Chronic Migraine |
| Lead sponsor | Teva Branded Pharmaceutical Products R&D, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Migraine |
| Intervention type | Drug |
| Interventions | Fremanezumab, Placebo |
| Enrollment | 1,130 |
| Start date | Mar 22, 2016 |
| Primary completion | Apr 11, 2017 |
| Completion | Apr 11, 2017 |
| First posted | Dec 4, 2015 |
| Last update posted | Nov 9, 2021 |
| Countries | Canada, Czechia, Finland, Israel, Japan, Poland, Russia, Spain, United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: